Racing the Clock: When the Genetic Carrier Seeks to Become the Architect of the Cure
The Rare360 Editorial Team · Feb 26
In rare disease, urgency is often discussed in abstract terms — pipeline acceleration, regulatory timelines, translational gaps. But for some, urgency has a date attached to it.
Yentli E. Soto Albrecht, PhD, is an MD-PhD student at the University of Pennsylvania whose life and work converged in August 2024 when her father — a 42-year educator in Lancaster, Pennsylvania — died from rapidly progressive ALS caused by the C9orf72 genetic mutation. He died fourteen months from his first symptom. She carries the same mutation and is determined not to let it take her the same way.
After pivoting from infectious disease research to neurodegeneration following her father’s death, Dr. Soto Albrecht built an eleven-project collaborative research portfolio spanning seven countries and twelve laboratories within a year. She is now co-launching the program CureC9 within EverythingALS.